UNSPSC 51144131: Dexamfetamine

This classification denotes a cns stimulant with the molecular formula C9H13N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier TZ47U051FI, chemically known as phenethylamine, alpha-methyl-, d- but more generally known as dexamfetamine, which bears U.S. National Institutes of Health Compound Identifier 5826. European Medicines Agency schedules Dexamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07019MIG. The term DEXAMFETAMINE is an International Non-Proprietary Name.

World Health Organization schedules dexamfetamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. DEXAMFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51144131 Dexamfetamine is a Commodity code that nominally names a single pharmaceutical product, but recent state and local solicitations using this code track to a broader portfolio of pharmaceutical procurement activity—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. The actual buying under the code spans health departments and human services agencies procuring emergency response medications, pharmacy benefit program managers sourcing generic and branded pharmaceuticals through authorized wholesalers, and specialized therapeutic initiatives. Issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across multiple states including Oregon). The code sees use across health-focused government agencies and cooperative purchasing vehicles rather than a concentrated set of repeat single buyers.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; vendors must include shipping and delivery costs and meet E-Verify and drug-free workplace certification requirements. Texas Health and Human Services Commission released RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between state pharmacy benefit programs and manufacturers outside traditional PBM and GPO channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for multiple contracts covering generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with contract awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness.